JPX · 4596.T
Kubota Pharmaceutical Holdings Co., Ltd.
¥57-¥1 (-1.72%)
Kubota Pharmaceutical Holdings Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 83.71% below the high.
Loading market information…
JPX · 4884.T · JPY
Stock price, earnings
Quote as of Oct 30, 2026, 06:30 AM UTC. Cached market data; not a live quote.
One-year closing-price history · JPY. Historical prices are not a forecast.
Kringle Pharma, Inc.’s quoted price sits in the upper half of its reported 52-week range, 24.56% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Kringle Pharma, Inc.’s next earnings report is currently expected on Nov 11, 2026. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Kringle Pharma, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Kringle Pharma, Inc. specializes in the innovation, production, and distribution of hepatocyte growth factor (HGF) protein-based therapeutics aimed at regenerative medicine. The company's cutting-edge HGF solutions are designed to address serious medical conditions including acute spinal cord injury, amyotrophic lateral sclerosis, vocal fold scars, and acute kidney injury. Founded in 2001, Kringle Pharma operates from its base in Ibaraki, Japan.
Latest available per-share figures in JPY. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:17 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
¥57-¥1 (-1.72%)
Kubota Pharmaceutical Holdings Co., Ltd.’s quoted price sits in the lower half of its reported 52-week range, 83.71% below the high.
¥363-¥6 (-1.63%)
Carna Biosciences, Inc.’s quoted price sits in the upper half of its reported 52-week range, 29.1% below the high.
¥64-¥2 (-3.03%)
Ribomic Inc.’s quoted price sits in the lower half of its reported 52-week range, 46.67% below the high.
¥215+¥1 (+0.47%)
Trans Genic Inc.’s quoted price sits in the lower half of its reported 52-week range, 55.85% below the high.
¥1,123-¥2 (-0.18%)
Miahelsa Holdings Corporation’s quoted price sits in the lower half of its reported 52-week range, 6.42% below the high.
¥828+¥9 (+1.1%)
Platz Co., Ltd.’s quoted price sits in the upper half of its reported 52-week range, 15.25% below the high.
¥658-¥4 (-0.6%)
Care Service Co.,Ltd.’s quoted price sits in the lower half of its reported 52-week range, 19.36% below the high.
¥276-¥7 (-2.47%)
Welby Inc.’s quoted price sits in the lower half of its reported 52-week range, 50.54% below the high.
